Champions Oncology Inc(CSBR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.08 | Insider Own | 56.22% | Shs Outstand | 13.9M | Perf Week | 4.59% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 6.1M | Perf Month | -4.02% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | - | Inst Own | 18.94% | Short Float | 1.12% | Perf Quarter | -17.41% |
| Income | -0.00B | P/S | 1.15 | EPS this Y | - | Inst Trans | -46.9% | Short Ratio | 6.16 | Perf Half Y | -18.4% |
| Sales | 0.06B | P/B | 17.91 | EPS next 5Y | - | ROA | -3.46% | Short Interest | 0.07M | Perf YTD | -27.5% |
| Book/sh | 0.28 | P/C | 15.99 | EPS past 3/5Y | 40.02% - | ROE | -29.83% | 52W High | -39.71% ($8.31) | Perf Year | -21.96% |
| Cash/sh | 0.31 | P/FCF | - | Sales past 3/5Y | 3.33% 7.68% | ROIC | -7.89% | 52W Low | 9.15% ($4.59) | Perf 3Y | -22.33% |
| Dividend Est. | - | EV/EBITDA | 213.66 | EPS Y/Y TTM | -136.61% | Gross Margin | 47.69% | Volatility(W/M) | 3.8% 5.16% | Perf 5Y | -50.54% |
| Dividend TTM | - | EV/Sales | 1.27 | Sales Y/Y TTM | 6.65% | Oper. Margin | -1.54% | ATR (14) | 0.24 | Perf 10Y | 205.49% |
| Dividend Ex-Date | - | Quick Ratio | 1.03 | EPS Q/Q | 3.16% | Profit Margin | -1.82% | RSI (14) | 48.92 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.03 | Sales Q/Q | 8.84% | SMA20 | 0.03% ($5.01) | Beta | 0.47 | Target Price | $12 |
| Payout | - | Debt/Eq | 2.82 | Earnings | 2026/9/10 | SMA50 | -1.61% ($5.09) | Rel Volume | 1.47 | Prev Close | $4.97 |
| Employees | 214 | LT Debt/Eq | 2.6 | EPS/Sales Surpr. | - | SMA200 | -15.5% ($5.93) | Avg Volume(3M) | 0.01M | Price | $5.01 |
| IPO | 1992/6/15 | Option/Short | Yes/Yes | Trades | 119 | Volume | 16,313 | Change | 0.8% |
챔피언스 온콜리지CSBR | NASD | Biotechnology 🔬 A U.S. biotech company that supports the development of new anticancer drugs using patient-derived tumor xenograft (PDX) models. Built on a tumor xenograft technology platform that implants human tumors into immunodeficient mice, this micro-cap stock provides preclinical research services and personalized oncology solutions to pharmaceutical and biotech clients.
Over the past 1 year, on the lower side
40% below its 1-year high.
Traded more than usual That is 147% of its average volume.
CSBR has weak earning power
Of every $100 in sales, $1.54 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $115. Peers typically go for $1,247. Compared with its own 3-year average, it is 542% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -50.5%. The S&P 500 did +79% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 18.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #398 of 592 in the industry
Based on market cap of $70M.
CING#397 Cingulate Inc $71M PER - CSBR#398 Champions Oncology Inc $70M PER - 
OSTX#398 OS Therapies Inc $70M PER - 
SPRO#400 Spero Therapeutics Inc $69M PER 10.9 
FBIO#401 Fortress Biotech Inc $68M PER 0.8 
FAQ
What kind of company is CSBR?
CSBR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CSBR?
The market cap of CSBR is approximately $70M, ranking 4,760 within its sector.
What is the 52-week high and low for CSBR?
CSBR has recorded a 52-week high of $8.31 and a low of $4.59.
